US › Healthcare

Evogene (EVGN)

US · Healthcare · Biotechnology

$0.39-2.50%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$347,000

Revenue YoY

-60.7%

Net profit

$-1.8M

EPS

$-0.13

EPS estimate

$-0.27

Net margin

-509.5%

EPS came in at -0.13 against a street estimate of -0.27 — a beat of 51.9%.

Key statistics

Market cap

$5.9M

Forward P/E

0.0

P/B

4.71

Book value

$-0.24

EPS (TTM)

$-1.55

52-week high

$1.35

52-week low

$0.35

50-day MA

$0.51

200-day MA

$0.71

Beta

0.72

Analyst view

Analysts rate Evogene a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $2.15.

Shareholding

Insiders

24.39%

Institutions

5.57%

Largest institutional holders

Fund	Stake
HRT FINANCIAL LLC	0.68%
Susquehanna International Group, LLP	0.51%
Citadel Advisors Llc	0.32%
XTX Topco Ltd	0.12%
UBS Group AG	0.07%
Daytona Street Capital LLC	0.06%
BNP Paribas Arbitrage, SA	0.02%
Morgan Stanley - Brokerage Accounts	0.01%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Evogene — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.